GeoVax Labs, a biotechnology company developing human vaccines, announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in support of its novel Zika vaccine development program.
The grant award of $300,000 will fund the second year of a two-year project period with a total budget of $600,000.
The grant, entitled “Advanced Preclinical Testing of a Novel Recombinant Vaccine Against Zika Virus”, supports advanced preclinical testing of GeoVax’s vaccine candidate (designated GEO-ZM02) in non-human primates in preparation for human clinical trials. GEO-ZM02 is a novel vaccine approach to protect against Zika virus (ZIKV), using GeoVax’s Modified Vaccinia Ankara (MVA) vector to express the ZIKV non-structural protein 1 (NS1).
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) vaccine platform. The Company’s development programs are focused on preventive vaccines against HIV, Zika virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for chronic hepatitis B infections and cancers. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection.